Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

214P - Landscape of homologous recombination repair gene mutations in different molecular subtypes of breast cancer

Date

16 Sep 2021

Session

ePoster Display

Presenters

Yan Xu

Citation

Annals of Oncology (2021) 32 (suppl_5): S447-S456. 10.1016/annonc/annonc688

Authors

Y. Xu1, Y. Jiang1, S. Zhang1, G. Zhang1, L. Zhou1, H. Zhang2, M. Yuan2, R. Chen2

Author affiliations

  • 1 Breast And Thyroid Surgery, Army Specialized Medical Center, 400038 - Chongqing/CN
  • 2 Medical Center, Geneplus-Beijing Institution, 102200 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 214P

Background

Breast cancer (BC) is one of the most prevalent malignancies throughout the world. Important therapeutic progress has been achieved over the past decade, and the identification of genomic alterations in the homologous recombination repair (HRR) pathway sensitizes tumors to therapeutics such as PARP inhibitors and platinum-based chemotherapy. Here we evaluated the characteristics of HRR related gene mutations in patients with different molecular subtypes of BC.

Methods

A total of 121 patients with BC were enrolled into the study. All samples were collected and detected by DNA based NGS with a 1021 gene panel which containing 36 HRR genes (CHEK1/2, BRCA1/2, BRIP1, CDK12, ATM/ATR, FANCA/C/D2/E/F/G/L/M, MRE11A, NBN, RAD50/51/52, RAD51B/C/D et al).

Results

121 patients (75 hormone receptor [HR]+, 29 triple-negative BC [TNBC], 17 human epidermal growth factor receptor 2 [HER2]+) were included. The proportions of HRR gene mutations in 3 subtypes of BC were 44.0% (33/75, HR+), 34.5% (10/29, TNBC) and 88.2% (15/17, HER2+), respectively. HRR genomic heterogeneity was found in the different molecular subtypes of BC. The top 5 mutated HRR genes in HR+ BC were BRCA2 (13/33, 39.4%), CDK12 (6/33, 18.2%), BRCA1 (5/33, 15.2%), NBN (5/33, 15.2%), ATM (4/33, 12.1%). In TNBC, the top 6 mutated HRR genes were BRCA1 (3/10, 30.0%), NBN (2/10, 20.0%), BRCA2 (1/10, 10.0%), ATRX (1/10, 10.0%), PALB2 (1/10, 10.0%). The most frequent HRR genetic alteration involve in HER2+ BC were CDK12 (9/15, 60.0%), BRIP1 (4/15, 26.7%), BRCA1 (3/15, 20.0%), BRCA2 (2/15, 13.3%), ATRX (1/15, 6.7%). Among the 65 HR+ BC patients receiving adjuvant therapy, 9 (9/65, 13.9%) patients received platinum-based adjuvant therapy. The medium follow-up time was 34 m (range 18-68 m). For the 3 patients who had relapsed, the 2 patients with HRR gene mutations had longer DFS (48 m and 68 m, respectively) than the other one without HRR gene mutations had shorter DFS (18 m).

Conclusions

In terms of HRR gene mutations, HR+, TNBC and HER2+ BC have different mutation landscape. Mutations in HRR genes may serve as a biomarker for platinum-based adjuvant therapy for HR+ BC patients, which warrants further studies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.